


# Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capita 2022, current international dollars PPP



Source: European Medicines Agency, IQVIA EFPIA Patients W.A.I.T. Indicator 2022 Survey, Apr 2023; International Monetary Fund, Oct 2023; IQVIA Institute, Jan 2024.

Notes: Includes cell and gene therapies approved as advanced therapy medicinal products (ATMPs) by the European Medicines Agency 2014–2021 (n=12).

Does not include products withdrawn from the market

Accessed at: <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies>